BMS to develop and market PDL's multiple myeloma antibody
PDL BioPharma (oncology and immune disease antibodies) has licensed Bristol-Myers Squibb worldwide rights to its Phase I CS1-targeting antibody elotuzumab for multiple myeloma.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.